Dyshidrotic Eczema: Blisters on Hands and Feet

Clinical Overview

Dyshidrotic eczema, also termed dyshidrosis, pompholyx, or vesicular hand dermatitis, is a recurrent inflammatory condition characterized by the development of small, intensely pruritic vesicles and bullae on the palms, soles, and lateral aspects of fingers and toes. The condition is named from the historical (now discredited) assumption that it resulted from abnormal sweat gland function (dyshidrosis literally meaning "bad sweating"). Despite this misnomer, the condition has no direct association with sweating abnormalities. Dyshidrotic eczema typically presents with a sudden onset of small fluid-filled blisters measuring 1-3 mm in diameter, accompanied by intense pruritus and burning sensations. The condition is episodic, with flares lasting 2-4 weeks followed by varying periods of remission. Peak incidence occurs in individuals aged 20-40 years, though the condition can present at any age, including childhood.

Epidemiology

Dyshidrotic eczema represents approximately 5-10% of all eczema cases and 20% of hand eczema cases in dermatology populations. Estimated prevalence in the general population ranges from 0.5% to 3.0%, with significant geographic variation. The condition shows slight female predominance (female-to-male ratio approximately 1.2:1). Environmental factors strongly influence disease activity: exposure to nickel, contact allergens, irritants, and stress are recognized triggering factors in 60-70% of patients. Occupational exposure significantly increases risk, particularly for individuals in healthcare, food service, cosmetology, and metalworking industries. Atopic history (atopic dermatitis, asthma, or allergic rhinitis) is present in 40-60% of patients. Seasonal variation is common, with worsening during spring and summer months in some patients and winter exacerbations in others. Specific triggers including nickel ingestion, particularly from dietary sources or dietary supplements, have been identified in 40-50% of nickel-sensitive individuals with dyshidrotic eczema.

Pathophysiology

The pathophysiology of dyshidrotic eczema involves multiple overlapping mechanisms. Impaired skin barrier function, manifested by elevated transepidermal water loss and altered lipid composition, creates increased susceptibility to irritants and allergens. Nickel sensitivity plays a central role in many cases: systemic nickel exposure through dietary sources (nuts, chocolate, soy, cocoa, shellfish) or dermal contact with nickel-containing objects can precipitate flares in nickel-sensitized individuals through a systemic contact dermatitis mechanism. Genetic predisposition is evidenced by familial clustering, with approximately 25% of patients reporting affected relatives. Histologically, the characteristic feature is acantholysis with intraepidermal blister formation, particularly within the lower epidermis, accompanied by intense inflammatory infiltrate including T lymphocytes, Langerhans cells, and variable numbers of neutrophils. Elevated interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNF-α) levels are found in affected skin and serum. Delayed-type hypersensitivity (Type IV) reactions to contact allergens, particularly nickel, chromium, and cobalt, contribute significantly to flares in sensitized individuals. Emotional stress modulates disease activity through neuroimmune pathways, increasing skin reactivity and pruritus.

Clinical Presentation

Dyshidrotic eczema presents with sudden onset of intensely pruritic vesicles and small bullae, typically measuring 0.5-3 mm in diameter, on the palms, soles, and lateral aspects of fingers and toes. The lesions may coalesce into larger bullae. The lateral fingers are most commonly affected, followed by palms, soles, and dorsal aspects of hands. The condition typically progresses through distinct stages: vesicular phase (days 1-3) characterized by appearance of small blisters; exudative phase (days 4-7) with rupture of vesicles resulting in maceration and oozing; and lichenification phase (weeks 2-4) with dry, scaly, thickened skin and pigmentary changes. Severe pruritus and burning sensations often precede visible lesions by 24 hours. Secondary bacterial infection occurs in 20-30% of cases, manifesting as increased erythema, purulent drainage, lymphangitis, or regional lymphadenopathy. Seasonal variation is notable, with many patients experiencing predictable exacerbations at specific times of year. Complete resolution typically occurs within 3-4 weeks, but recurrences are frequent, with up to 80% of patients experiencing multiple flares within a 12-month period. Some patients develop chronic disease with almost continuous low-grade vesicular activity.

Diagnosis

Diagnosis of dyshidrotic eczema is primarily clinical, based on characteristic presentation of recurrent vesicles on palms and soles without involvement of dorsal hands or feet. Key diagnostic criteria include: (1) sudden onset of pruritic vesicles on palms, soles, or lateral digits; (2) location distinct from other body areas; (3) episodic nature with periods of remission; (4) absence of features suggestive of systemic disease or infection. Patch testing should be performed to identify contact allergen sensitization, particularly to nickel, chromium, and cobalt, which are implicated in 60-80% of dyshidrotic eczema cases. The International Contact Dermatitis Research Group (ICDRG) standard series testing is recommended, with consideration of extended allergen panels in occupational exposures. Prick testing for aeroallergens may be helpful in patients with prominent seasonal variation. Potassium hydroxide (KOH) preparation and fungal culture should be obtained to exclude tinea pedis, which may present similarly on soles. Bacterial culture is indicated if secondary infection is suspected. Skin biopsy demonstrating acantholysis with intraepidermal blister formation can confirm diagnosis when clinical uncertainty exists. Nickel patch test (nickel sulfate 5.0% aqueous) should be performed routinely. Serum-specific IgE testing for aeroallergens may be considered if seasonal variation is prominent. Complete blood count with differential and comprehensive metabolic panel should be obtained before initiating systemic immunosuppressive therapy.

Treatment Algorithm

Initial management prioritizes identification and elimination of specific triggers. Patients should undergo comprehensive patch testing to identify contact allergen sensitization; identified allergens should be strictly avoided. For nickel-sensitive patients, dietary nickel restriction may significantly reduce flare frequency. Recommended low-nickel diet includes avoidance of nuts, chocolate, soy, shellfish, cocoa, and canned foods, while favoring fresh vegetables, fruits, meats, and dairy products. Barrier repair using fragrance-free, hypoallergenic emollients is essential. Recommended products include CeraVe Lotion, Eucerin Lotion, or plain petrolatum applied 2-3 times daily and after water exposure.

For acute vesicular flares, short courses of topical corticosteroids are first-line therapy. Medium-to-high potency agents are appropriate given the thick epidermis of palms and soles: triamcinolone acetonide 0.1% cream twice daily for 1-2 weeks, or clobetasol propionate 0.05% cream twice daily for 7-10 days for severe cases. Occlusion with plastic wrap or specialized occlusive dressings enhances penetration and efficacy.

Topical calcineurin inhibitors including tacrolimus 0.1% ointment twice daily or pimecrolimus 1% cream twice daily are valuable steroid-sparing alternatives, particularly for maintenance therapy and prevention of flares. These agents do not cause skin atrophy with prolonged use.

Wet dressings using cool, isotonic saline solution (0.9% sodium chloride) applied for 10-15 minutes, 2-3 times daily, reduce acute inflammation and provide symptomatic relief. Potassium permanganate (1:10,000 solution) dressings are beneficial if secondary bacterial infection is present, applied for 10-15 minutes twice daily.

Pruritus management is critical for preventing further trauma and secondary infection. First-generation antihistamines including hydroxyzine 25-50 mg at bedtime improve sleep quality and reduce nocturnal scratching. Topical antipruritics including pramoxine 1% lotion or menthol 1-2% preparations provide temporary symptom relief.

For chronic, recurrent dyshidrotic eczema inadequately responsive to topical therapy and trigger avoidance, systemic agents are considered. Systemic corticosteroids (prednisone 0.5-1.0 mg/kg/day, maximum 60 mg daily, tapered over 2-4 weeks) effectively control acute severe flares but should not be used for maintenance due to cumulative adverse effects. Oral cyclosporine at 2.5-5.0 mg/kg/day divided in two doses demonstrates efficacy in 70-80% of patients with chronic disease, with response evident within 2-4 weeks. Azathioprine 1.5-2.5 mg/kg/day is an alternative with slower onset but acceptable efficacy. Mycophenolate mofetil (MMF) 1000-1500 mg twice daily shows promise. Dupilumab at standard dosing (600 mg initial loading dose followed by 300 mg every 2 weeks) has demonstrated efficacy in clinical trials for chronic hand eczema.

Secondary bacterial infections require prompt management. Culture-guided antibiotic therapy is preferred; for empiric treatment, oral cephalexin 500 mg four times daily or clindamycin 300-450 mg three times daily for 10-14 days is appropriate for non-severe infections. For methicillin-resistant Staphylococcus aureus (MRSA), trimethoprim-sulfamethoxazole (TMP-SMX) double-strength tablet twice daily for 10-14 days or doxycycline 100 mg twice daily is recommended.

Prognosis

The prognosis of dyshidrotic eczema is highly variable. Approximately 25-30% of patients experience spontaneous remission within 5 years, 40% continue with periodic flares controlled by trigger avoidance and topical therapy, and 30% develop chronic persistent disease. Factors influencing prognosis include identification and avoidance of specific triggers (particularly nickel sensitization), occupational exposure (those in high-exposure occupations have longer disease duration and higher relapse rates), stress management, and adherence to skin barrier repair. Early onset disease (before age 20) is associated with higher chronicity rates. Patients with prominent nickel sensitization who successfully implement dietary and contact restriction show significant improvement in disease frequency and severity. Psychological factors including stress perception and coping mechanisms influence disease course, with stress management potentially reducing flare frequency by 30-50%. Development of secondary bacterial infection may result in brief periods of disease exacerbation but does not alter long-term prognosis if treated promptly. Scarring is uncommon unless severe lichenification with marked trauma occurs.

When to See a Dermatologist

Initial dermatologic evaluation is recommended for suspected dyshidrotic eczema to confirm diagnosis and initiate patch testing for allergen identification. Urgent evaluation is indicated if: (1) lesions demonstrate signs of cellulitis or systemic infection; (2) disease is severe and affecting significant percentage of palms/soles, causing functional impairment; (3) patient develops signs of systemic toxicity; (4) significant diagnostic uncertainty exists. Ongoing specialist care is appropriate if: (1) patch testing reveals multiple allergen sensitizations requiring comprehensive guidance on avoidance; (2) disease is chronic and recurrent, requiring systemic therapy; (3) occupational assessment and workplace accommodations are needed; (4) systemic immunosuppressive agents are being initiated or monitored; (5) secondary complications including severe infection or development of new dermatologic diagnoses occur.

Frequently Asked Questions

Q: Does sweating trigger dyshidrotic eczema? A: Despite the historical name "dyshidrosis," the condition is not directly caused by or related to sweat gland dysfunction. However, excessive sweating, heat exposure, or occlusion (such as from wearing gloves in hot, humid conditions) may trigger or exacerbate flares in susceptible individuals. Patients benefit from keeping hands and feet cool and dry and avoiding excessive sweating when possible.

Q: Can diet affect dyshidrotic eczema? A: Yes, dietary nickel content significantly affects dyshidrotic eczema flares in nickel-sensitized individuals. Nickel is present in high concentrations in nuts, chocolate, soy products, shellfish, cocoa, and canned foods. A low-nickel diet has been shown to reduce flare frequency in 40-50% of nickel-sensitive patients. Additionally, dietary supplementation with nickel may precipitate flares; patients should verify that supplements are nickel-free.

Q: How is dyshidrotic eczema different from other hand eczemas? A: Dyshidrotic eczema is distinguished by its vesicular presentation predominantly on lateral digits and palms, with acute onset of small blisters and characteristic episodic pattern. Other hand eczemas including irritant contact dermatitis, allergic contact dermatitis, and seborrheic dermatitis typically present with poorly-demarcated erythema and scaling without prominent vesiculation, and involve different body areas. Proper diagnosis requires clinical assessment and often patch testing.

Q: Is occupational exposure a significant factor? A: Yes, occupational exposure to irritants and allergens is a major contributory factor in 40-60% of dyshidrotic eczema cases, particularly in healthcare workers, food service employees, cosmetologists, and metalworkers. Workplace modifications including use of protective gloves, frequent barrier repair with emollients, and allergen avoidance may significantly reduce disease activity. Occupational assessment by a dermatologist experienced in occupational disease is often beneficial.

References